TcL Pharma SAS - Product Pipeline Review - Q4 2010

Date: December 1, 2010
Pages: 23
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: TE7EE5DADDFEN
Leaflet:

Download PDF Leaflet

TcL Pharma SAS - Product Pipeline Review - Q4 2010
TcL Pharma SAS – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “TcL Pharma SAS – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • TcL Pharma SAS – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of TcL Pharma SAS human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of TcL Pharma SAS with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the TcL Pharma SAS’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate TcL Pharma SAS’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of TcL Pharma SAS in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the TcL Pharma SAS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with TcL Pharma SAS.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of TcL Pharma SAS and identify potential opportunities in those areas.
TcL Pharma SAS Snapshot
TcL Pharma SAS Overview
Key Information
Key Facts
TcL Pharma SAS – Research and Development Overview
Key Therapeutic Areas
TcL Pharma SAS – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
TcL Pharma SAS – Pipeline Products Glance
TcL Pharma SAS–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
TcL Pharma SAS – Drug Profiles
FR104
  Product Description
  Mechanism of Action
  R&D Progress
MF280
  Product Description
  Mechanism of Action
  R&D Progress
MD707
  Product Description
  Mechanism of Action
  R&D Progress
MP196
  Product Description
  Mechanism of Action
  R&D Progress
TcL Pharma SAS – Pipeline Analysis
TcL Pharma SAS – Pipeline Products by Therapeutic Class
TcL Pharma SAS Pipeline Products By Target
TcL Pharma SAS – Pipeline Products by Molecule Type
TcL Pharma SAS – Locations And Subsidiaries
Head Office
Financial Deals Landscape
TcL Pharma SAS, Deals Summary, 2004 to 2010
TcL Pharma SAS Detailed Deal Summary
TcL Pharma Enters Into Co-Development Agreement With Lonza Group
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 2

LIST OF TABLES

TcL Pharma SAS – Pipeline by Therapy Area and Indication, 2010
TcL Pharma SAS – Pipeline by Stage of Development, 2010
TcL Pharma SAS – Monotherapy Products in Pipeline, 2010
TcL Pharma SAS - Pipeline By Therapeutic Class, 2010
TcL Pharma SAS - Pipeline By Target, 2010
TcL Pharma SAS – Pipeline By Molecule Type, 2010
TcL Pharma SAS, Deals Summary, 2004 to 2010
TcL Pharma Enters Into Co-Development Agreement With Lonza Group 21

LIST OF FIGURES

TcL Pharma SAS – Pipeline by Therapy Area and Indication, 2010
TcL Pharma SAS – Pipeline by Stage of Development, 2010
TcL Pharma SAS – Monotherapy Products in Pipeline, 2010
TcL Pharma SAS – Pipeline By Therapeutic Class, 2010
TcL Pharma SAS - Pipeline By Target, 2010
TcL Pharma SAS – Pipeline By Molecule Type, 2010 18

Ask Your Question

TcL Pharma SAS - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: